Back to top

Keryx Biopharmaceuticals (KERX) Enters Overbought Territory
September 18, 2013

Read MoreHide Full Article
Keryx Biopharmaceuticals (KERX - Free Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because KERX is now in overbought territory with an RSI value of 71.37. Furthermore, estimates for the Keryx Biopharmaceuticals have been coming down, pushing it to a Zacks Rank #4 (Sell). This suggests that investors may better off exiting this stock before it falls back to Earth.



In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Keryx Biopharmaceuticals, Inc. (KERX) - free report >>


More from Zacks Tale of the Tape

You May Like